Tina Nuebling

Tuebingen, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity.

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity.

Journal: Neoplasia (New York, N.Y.)

Published: June 27, 2018

The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.

The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.

Journal: Cancer immunology research

Published: April 25, 2017

Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML.

Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML.

Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research

Published: June 11, 2016

Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.

Expression of RANK-L and in part of PD-1 on blasts in patients with acute myeloid leukemia correlates with prognosis.

Journal: European journal of haematology

Published: April 07, 2016

Death Receptor Expression on Blasts in AML Is Associated with Unfavorable Prognosis.

Death Receptor Expression on Blasts in AML Is Associated with Unfavorable Prognosis.

Journal: Anticancer research

Published: July 01, 2015

Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.

Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: July 03, 2014

Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells.

Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells.

Journal: Molecular cancer therapeutics

Published: August 09, 2013

Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: February 06, 2013

Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.

Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: December 18, 2012

RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.

RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.

Journal: Cancer research

Published: November 10, 2012

Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.

Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: June 26, 2012

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.

Journal: Leukemia

Published: February 01, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026